ABSTRACT: Streptococcus agalactiae is a major piscine pathogen that causes significant morbidity and mortality among numerous species of freshwater, estuarine and marine fishes. Considering the economic importance of fishes susceptible to S. agalactiae throughout the world, an efficacious S. agalactiae vaccine was developed using an extracellular product (ECP) fraction and formalinkilled whole cells of S. agalactiae. A vaccine study was conducted by intraperitoneal (i.p.) injection in Nile tilapia Oreochromis niloticus in order to determine the duration of protection and its correlation to antibodies specific for this pathogen. After 47, 90 or 180 d post-vaccination (DPV), the fish were i.p. challenged with approximately 2.0 × 10 4 S. agalactiae colony-forming units (CFU) fish -1 to determine the duration of protective immunity. The percent survival in control fish i.p.-injected with sterile TSB was 16, 16, and 4% on 47, 90 and 180 DPV, respectively, while the percent survival for the vaccinated fish was 67, 62 and 49%, respectively. The specific mean antibody concentration of the vaccinated fish was significantly higher than that of the control fish, with significant correlation between the ELISA optical density (OD) and protection. These results indicate that the specific antibody has a correlation with protection following immunization with the S. agalactiae vaccine and that the vaccine can confer protection against S. agalactiae up to 180 DPV.
INTRODUCTION
The Group B streptococcal fish pathogen Streptococcus agalactiae affects numerous freshwater, estuarine and marine fish species, including golden shiners Notemigonus crysoleucas (Mitchill) (Robinson & Meyer 1966) , menhaden Brevoortia patronus (Goode) (Plumb et al. 1974) , sea trout Cynoscion regalis (Bloch & Schneider) , striped bass Morone saxatilis (Walbaum) (Baya et al. 1990 ), seabream Sparus auratus L., tilapia Oreochromis niloticus L., mullet Liza klunzingeri (Day) and silver pomfret Pampus argenteus (Euphrasen) (Duremdez et al. 2004) . Several streptococcal isolates have been reported in recent years, including isolates from the United States (Plumb et al. 1974) , Israel (Eldar et al. 1994) and Kuwait . Some of these isolates were initially unspeciated or misidentified as S. difficile, but were subsequently characterized as S. agalactiae (Wilkinson et al. 1973 , Vandamme et al. 1997 , Kawamura et al. 2005 . Additionally, different isolates of S. agalactiae show significant homogeneity according to biochemical characteristics, whole-cell protein profiles, and certain nucleic acid sequences (Elliott et al. 1990 , Vandamme et al. 1997 , Berridge et al. 2001 , Kawamura et al. 2005 .
A number of environmental factors, including warm water temperatures, increased ammonia levels and low dissolved oxygen levels, play an important role in Streptococcus agalactiae outbreaks , Evans et al. 2003 . Clinical signs of disease include anorexia, 'C'-shaped body posturing and erratic swimming, and many outbreaks cause considerable mortalities . Because of the economic importance of fishes affected by this pathogen, an effective vaccine could help decrease related fish losses. Evans et al. (2004a,b ) assessed a killed vaccine composed of concentrated extracellular products (ECP) and formalin-killed S. agalactiae whole cells. Tilapia injected with this vaccine were significantly protected against S. agalactiae challenge. However, the protective effects were assessed only through 28 to 64 d post-vaccination (Evans et al. 2004a,b) . To achieve a more comprehensive analysis of the duration of protective immunity following S. agalactiae vaccination, we have analyzed the duration of serum antibody responses and survival after S. agalactiae challenge at 47, 90 and 180 d post-vaccination (DPV) following a single intraperitoneal (i.p.) immunization. The production cycle of farmed tilapia in tropical regions can be completed in 4 to 6 mo (Stickney 2000) , and the vaccine must provide significant long-term protection against S. agalactiae. Thus, our objective was to determine the duration of immunity conferred using this S. agalactiae vaccine for 180 DPV following a single i.p. injection.
MATERIALS AND METHODS

Fish.
Nile tilapia Oreochromis niloticus with a mean weight of 45.5 ± 12.2 g were housed at the United States Department of Agriculture/Agriculture Research Service Aquatic Animal Health Laboratory in Chestertown, Maryland. The fish were kept in 57 l glass aquaria supplied with flow-through dechlorinated tap water and were maintained on a 12:12 h light:dark period. The fish were fed daily to satiation with Aquamax Grower 400. Daily water temperature averaged 30.83 ± 1.32°C, mean daily dissolved oxygen was 3.16 ± 0.83 mg l -1 , mean pH was 7.03 ± 0.13, and mean total ammonia concentration was 0.79 ± 0.68 mg l -1 . Vaccination. The vaccine was prepared as previously described (Evans et al. 2004a,b) . Briefly, the polysaccharide-encapsulated Streptococcus agalactiae was grown in tryptic soy broth (TSB; Difco Laboratories) at 27°C for 72 to 125 h. The resulting cultures were treated with 3% neutral buffered formalin for 24 h and then centrifuged to separate the cell pellet and culture fluid. The vaccine ECP fraction of the vaccine was prepared by concentrating the cell-free culture fluid containing ECP on a 3 kDa Amicon column (S3Y3) using a Millipore Proflux M12 (Millipore), and sterilized using a 0.22 µm 1 l microbiological filter (Corning).
Triplicate groups of 15 fish each were injected intraperitoneally (i.p.) with 0.1 ml of the Streptococcus agalactiae vaccine, and additional triplicate groups of 15 fish each were injected i.p. with 0.1 ml sterile TSB to serve as control groups. After injection, all fish were sequestered in groups of vaccinated or control fish (N = 15) in separate aquaria and maintained as previously described.
Experimental challenge. Fish from the vaccine and TSB control groups were challenged i.p. with 1.93 × 10 4 , 1.89 × 10 4 or 2.11 × 10 4 Streptococcus agalactiae colony-forming units (CFU) fish -1 on 47, 90 or 180 DPV, respectively. During each challenge period, fish were monitored daily for clinical signs of disease and mortality for 25 d post-challenge. Moribund and dead fish were removed twice daily, and bacterial samples were aseptically obtained from the naris, brain, head kidney and intestine of 10% of morbid and dead fish to confirm the presence of S. agalactiae. Samples were cultured at 35°C for 24 h on 5% de-fibrinated sheep blood agar (SBA; Remel), and isolate identity was confirmed as S. agalactiae using the BIOLOG MicroLog Microbial Identification System according to the manufacturer's instructions. Positive cultures were beta-haemolytic, oxidase-negative, catalase-negative, and Gram-positive cocci .
ELISA. On 0, 47, 90 and 180 DPV and 25 d postchallenge, tilapia inoculated with TSB or Streptococcus agalactiae vaccine were bled from the caudal vein and the sampled blood was held at 25°C for 1 h. Serum was separated by centrifugation at 400 × g for 6 min and then stored at -70°C until use. The tilapia serum was tested for antibodies against sonicated whole S. agalactiae cells by indirect ELISA based on the methods of Shelby et al. (2002) . The ELISA antigen was prepared by sonication of whole encapsulated S. agalactiae cells followed by centrifugation at 4000 × g for 20 min and removal of the supernatant. The total protein content of this fraction was determined by the bicinchoninic acid method and adjusted to 500 µg protein ml -1 . One hundred µl of antigen was added to each well of a 96-well microtiter plate, which was incubated at 25°C for 2 h. The wells were blocked with a 3% bovine serum albumin (Sigma) at 25°C for 1 h, and the plates were washed with phosphate-buffered saline plus 0.05% Tween-20 (PBS-T). Nile tilapia serum samples were diluted 1:100 in PBS-T, and 100 µl of the resulting solution was added to 3 replicate wells of the microtiter plate. The plate was incubated at 25°C for 1 h and washed with PBS-T. Mouse anti-tilapia IgM heavy chain-specific monoclonal antibody 1H1 (Shelby et al. 2002) was diluted 1:5000 in PBS-T and 100 µl of this solution was added to each well. The plate was incubated at 25°C for 1 h and washed with PBS-T. Peroxidase-conjugated rabbit anti-mouse IgG (Pierce Biotechnology) was diluted 1:5000 in PBS-T and added to each well. The plate was washed again and 100 µl of One-Step Ultra TMB-ELISA (Pierce) was added to each well. The ELISA reaction was stopped after 20 min with 50 µl 3 M H 2 SO 4 , and the optical density of the reactions was read at 450 nm with a Bio-Tek Automated Microplate Reader (Bio-Tek Instruments).
Statistics. All statistical analyses were performed using the SAS program (SAS Institute). Survival data and ELISA results (mean ± SE) were compared with the general linear model (GLM) procedure, and significant differences between groups and between tanks within groups were accepted at p < 0.05.
RESULTS
Behaviorally, control and vaccinated fish began to display clinical signs of disease 24 h after each challenge, and almost all mortalities in both groups occurred during the first 5 d postchallenge. Over the course of the 3 challenge periods, the control group experienced 84 to 96% mortalities while the vaccinated group experienced 33 to 51% mortalities. Within the 25 d observation period of the challenge study, the mean days of survival ranged from 2.4 to 5.3 d for the controls and 13.3 to 17.3 d for the vaccinates (Table 1) . Percent survival and days of survival between control and vaccine groups at each challenge period were significantly different. The percent survival in control fish injected with sterile TSB was 16, 16 and 4% on 47, 90 and 180 DPV, respectively, while the percent survival for the vaccinated fish was 67, 62 and 49%, respectively. While the overall percent survival and mean days of survival for each group generally decreased over time, no significant differences were found when comparing the survival data for each group from the 3 challenge periods. A tank effect (p = 0.0111) was observed when comparing the mean days of survival for control fish from the 47 DPV challenge, but no tank effect was detected when comparing the percent survival for this group. No other significant tank effects were noted when analyzing survival data. All sampled organs from all sampled fish from each group were culture-positive for Streptococcus agalactiae.
On 47, 90 and 180 DPV, the TSB-injected controls also did not exhibit increased Streptococcus agalactiae-specific antibody concentrations, but the fish immunized with the S. agalactiae vaccine showed significant increases in mean specific anti-S. agalactiae antibody concentrations from 0.019 ± 0.002 to 0.115 ± 0.004 optical density (OD) between 0 and 47 DPV, respectively ( 
DISCUSSION
The aim of this research was to correlate the specific anti-Streptococcus agalactiae antibody concentrations in immunized tilapia with their ability to resist experimental challenge with highly virulent S. agalactiae. Klesius et al. (2006) reviewed experimental vaccines for streptococcal disease in fishes, revealing that only a limited number of the reviewed studies assessed the long-term protection conferred by vaccination and that no prior studies have evaluated the correlation between antibody concentrations and survival after S. agalactiae challenge. Eldar et al. (1997) i.p. injected rainbow trout Oncorhynchus mykiss with a formalinkilled preparation of S. iniae and determined that the vaccine conferred protection against S. iniae challenge up to 6 mo post-vaccination. Specific anti-S. iniae antibody levels, however, decreased over time after vaccination from a titer of 1:20 to 1:1. Romalde et al. (1999) studied a toxoid-enriched Streptococcus sp. bacterin and found that protection conferred by the vaccine declined with time. Percent survival rates among vaccinated fish were 90, 75 and 50% after challenge at 6, 12 and 24 mo post-vaccination, respectively. Despite significant protection, Romalde et al. (1999) failed to find a correlation between specific antibody concentrations and protective immunity. Klesius et al. (2000) evaluated an S. iniae vaccine (US Patent No. 6 379 677 B1; 2002) with formalin-killed cells and concentrated extracellular products, and this vaccine conferred significant protection against challenge for at least 6 mo. Protection appeared associated with increased specific antibody levels, but the correlation was not reflective of protective immunity.
According to the percent survival and mean days of survival, the Streptococcus agalactiae vaccine studied herein provided significant protection against experimental challenges with S. agalactiae between 47 and 180 DPV. This finding extends the conclusions previously indicated by Evans et al. (2004b) , who observed that protection conferred by this vaccine was comparable at 30 and 64 DPV and suggested that longer duration of protective immunity may be possible. In another study with this S. agalactiae vaccine, Evans et al. (2004a) observed a 90% survival rate among vaccinated tilapia (mean weight = 39.0 g) held at 30°C and challenged with 1.5 × 10 4 S. agalactiae CFU fish -1
. The percent survival in the current study was generally lower than survival observed previously, but our experimental challenge dose (approximately 2.0 × 10 4 S. agalactiae CFU fish -1 ) was higher than those in previous studies, which may account for the lower percent survival. Indeed, Evans et al. (2004a,b) found that control fish administered 1.5 × 10 4 S. agalactiae CFU fish -1 had 24 to 40% survival rates, while control fish administered 2.6 × 10 4 S. agalactiae CFU fish -1 had a 0% survival rate. The challenge dose used in the present study fell between these 2 previously used challenge doses, and our control fish accordingly had 4 to 16% survival rates. The ultimate decrease to a 47% survival rate among vaccinated fish at 180 DPV is probably due to the use of a challenge dose greater than the S. agalactiae LD 50 dose (1.9 × 10 3 S. agalactiae CFU fish -1 ; Evans et al. 2002) .
As in other vaccine studies in which protection against other pathogen species was directly correlated with serum antibody concentrations (Gudmundsdottir et al. 1997 , Bricknell et al. 1999 ), significant correlations were found in this study between anti-Streptococcus agalactiae antibody concentrations and percent survival. The statistical results of the present study demonstrate that the specific antibody responses significantly correlated with percent survival at 47, 90 and 180 DPV and that the antibody concentrations and percent survival declined at 180 DPV. This correlation between specific antibody titers and protection was substantiated by statistical analysis (p < 0.05). Although the percent survival from 47 to 90 DPV decreased, the decrease was not statistically significant; meanwhile, the ELISA OD increased significantly, but may have not been high enough to increase survival significantly. Therefore, the correlation at 90 DPV was not as strong, but was still significant. This study also does not definitively discount the role of other immune factors that are protective against other Streptococcus sp., such as nonspecific cytotoxic cells (Taylor et al. 2001 ). However, our conclusions correspond with previous studies that have shown that mammalian immunity against S. agalactiae is based on a specific antibodydependent phagocytic response by polymorphonuclear cells .
Post-challenge specific antibody concentrations were significantly increased in response to experimental challenge, even at 180 DPV. Although the post-challenge levels of control and vaccinated groups were generally equivocal, the vaccinated fish may have generated immune responses more rapidly. This presumptively protected the vaccinated fish against mortalities while the control fish were not able to generate rapid specific antibody responses and experienced high mortalities within 5 d of challenge. In addition, because challenge increased post-challenge specific antibody concentrations in control fish, exposure of vaccinated fish to Streptococcus agalactiae present in aquaculture systems would be expected to booster the antibody concentrations. This booster effect would increase the levels of protection over time. The use of adjuvant or immunization booster may be required to protect tilapia during production periods longer than 6 mo, but the reduced degree of immunity at 180 DPV may be sufficient to protect fish exposed to S. agalactiae in aquaculture production systems.
In conclusion, the current study found good correlation between specific anti-Streptococcus agalactiae antibody concentrations and survival following S. agalactiae challenge, despite the decline in both parameters at 180 DPV. Furthermore, because of the positive correlation between specific antibody concentrations and survival, antibody levels could be measured as a non-lethal monitoring tool to assess the potential degree of protection and the efficacy of vaccination.
